Article

Membrane-Bound Complement Regulatory Proteins as Biomarkers and Potential Therapeutic Targets for SLE

Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
Advances in Experimental Medicine and Biology (Impact Factor: 2.01). 01/2013; 735:55-81. DOI: 10.1007/978-1-4614-4118-2_4
Source: PubMed

ABSTRACT For the last two decades, there had been remarkable advancement in understanding the role of complement regulatory proteins in autoimmune disorders and importance of complement inhibitors as therapeutics. Systemic lupus erythematosus is a prototype of systemic autoimmune disorders. The disease, though rare, is potentially fatal and afflicts women at their reproductive age. It is a complex disease with multiorgan involvement, and each patient presents with a different set of symptoms. The diagnosis is often difficult and is based on the diagnostic criteria set by the American Rheumatology Association. Presence of antinuclear antibodies and more specifically antidouble-stranded DNA indicates SLE. Since the disease is multifactorial and its phenotypes are highly heterogeneous, there is a need to identify multiple noninvasive biomarkers for SLE. Lack of validated biomarkers for SLE disease activity or response to treatment is a barrier to the efficient management of the disease, drug discovery, as well as development of new therapeutics. Recent studies with gene knockout mice have suggested that membrane-bound complement regulatory proteins (CRPs) may critically determine the sensitivity of host tissues to complement injury in autoimmune and inflammatory disorders. Case-controlled and followup studies carried out in our laboratory suggest an intimate relation between the level of DAF, MCP, CR1, and CD59 transcripts and the disease activity in SLE. Based on comparative evaluation of our data on these four membrane-bound complement regulatory proteins, we envisaged CR1 and MCP transcripts as putative noninvasive disease activity markers and the respective proteins as therapeutic targets for SLE. Following is a brief appraisal on membrane-bound complement regulatory proteins DAF, MCP, CR1, and CD59 as biomarkers and therapeutic targets for SLE.

0 Bookmarks
 · 
137 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The immune system has the challenging tasks to discriminate self from non-self, but also to discern harmless from harmful foreign antigens or entities and to attack and eliminate foreign threats. In the classical view the immune system can be divided into an innate and adaptive branch, where the innate immune system represents a quick first-line defense against pathogens, whereas the adaptive immune system is slower, but more diverse and sophisticated, able to memorize pathogens, and confer long-lasting immunity to the host. The innate immune system relies on recognition of evolutionarily conserved pathogen-associated molecular patterns (PAMPs) by innate pattern recognition molecules and receptors (PRMs and PRRs), whereas the adaptive immune system is principally trained to recognize foreign molecules and to memorize them by highly adapted, specific receptor molecules.
    Comparative Medicine: Anatomy and Physiology, 1 edited by Erika Jensen-Jarolim, 12/2013: chapter 13.1: pages 220-242; Springer., ISBN: ISBN 978-3-7091-1559-6 (ebook)
  • [Show abstract] [Hide abstract]
    ABSTRACT: Within the past years, we have witnessed a great improvement in mass spectrometry (MS) and proteomics approaches in terms of instrumentation, protein fractionation, and bioinformatics. With the current technology, protein identification alone is no longer sufficient. Both scientists and clinicians want not only to identify proteins but also to identify the protein's posttranslational modifications (PTMs), protein isoforms, protein truncation, protein-protein interaction (PPI), and protein quantitation. Here, we describe the principle of MS and proteomics and strategies to identify proteins, protein's PTMs, protein isoforms, protein truncation, PPIs, and protein quantitation. We also discuss the strengths and weaknesses within this field. Finally, in our concluding remarks we assess the role of mass spectrometry and proteomics in scientific and clinical settings in the near future. This chapter provides an introduction and overview for subsequent chapters that will discuss specific MS proteomic methodologies and their application to specific medical conditions. Other chapters will also touch upon areas that expand beyond proteomics, such as lipidomics and metabolomics.
    Advances in Experimental Medicine and Biology 01/2014; 806:1-32. DOI:10.1007/978-3-319-06068-2_1 · 2.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent evidence implicated an important role of Th17 cells in the pathogenesis of systemic lupus erythematosus (SLE). However, the association between dynamic changes of Th17 cell frequency and clinical parameters in SLE patients receiving clinical managements remains unknown. Here, we sought to evaluate their correlation in Chinese new-onset SLE patients with standard therapy. We found that the frequency of Th17 cells was higher in SLE patients than that in healthy controls and could be decreased by standard care. In consistent, the level of serum IL-6, IL-1β, IL-23, and Stat3 activity was elevated in SLE patients and down-regulated by disease treatment. Of note, the frequency of Th17 cells was correlated with SLEDAI and serum C3 in SLE patients. The changes of Th17 cell frequency were associated with those of SLEDAI and serum C3 in SLE patients between pretreatment and posttreatment. Further, the Th17 cell frequency was positively correlated with serum anti-dsDNA antibody in SLE patients. The changes of Th17 cell frequency were associated with those of serum anti-dsDNA antibody in SLE patients. Our findings showed that dynamic frequencies of Th17 cells were closely correlated with clinical parameters in SLE patients receiving standard treatment, which could facilitate the efficient management and development of novel therapeutics for SLE.
    Clinical Rheumatology 05/2014; 33(10). DOI:10.1007/s10067-014-2656-5 · 1.77 Impact Factor